For months, medical oncologist Georgina Long has closely guarded data that could mark a turning point in cancer treatment. As the director of the Melanoma Institute Australia and chair of melanoma medical oncology and translational research at the University of Sydney, she is set to present the results of a global phase three clinical trial of a personalized mRNA cancer vaccine, developed by Moderna, at the upcoming European Society of Medical Oncology annual congress.
The vaccine, known as intismeran, is designed as an individualized neo-antigen therapy that targets melanoma tumors. When administered alongside checkpoint inhibitor drugs, the vaccine demonstrated a 42 percent reduction in the risk of cancer recurrence or death among treated patients. These findings suggest a potentially transformative advance in managing melanoma, representing one of the most significant developments in cancer therapy since the advent of immunotherapies.
Professor Long led the trial’s steering committee, overseeing a study that spanned multiple countries and involved a large, diverse patient population. She describes the breakthrough as akin to the “first flight” — a foundational achievement that may extend beyond melanoma to impact other forms of cancer. Her goal is to reduce what she terms the “third space” — the group of patients who currently lack curative treatment options.
Speaking from Madrid prior to the presentation, Long emphasized the broader implications of the vaccine. “You can use this concept in any cancer,” she said. “We need to understand why we’re curing some patients and others are dying. It’s not for want of trying. We just haven’t had the tools, but we’re getting there now.”
The personalized vaccine approach involves tailoring treatment to the unique neo-antigens present on a patient's tumor cells, enabling the immune system to better recognize and attack cancer. This contrasts with traditional therapies that apply the same treatment broadly across patients with similar cancer types.
Moderna’s intismeran vaccine represents a novel application of mRNA technology, which has gained prominence in recent years through its role in COVID-19 vaccines. Its success in this melanoma trial may pave the way for further development of therapeutic cancer vaccines.
As Professor Long prepares to reveal these results to the international oncology community, the data herald a hopeful shift for patients who previously faced limited options. The ongoing research underscores a growing era of precision medicine, leveraging advances in immunology and genomics to deliver more effective, individualized cancer treatments.